Prestige Consumer Healthcare Inc. Reports Fiscal 2027 Second Quarter Results
Q2 Revenue of $336.3 million, up 22.7% versus prior yearQ2 Diluted EPS of $0.53; Adjusted Diluted EPS of $1.13, compared to prior year Adjusted ...
Model output · Signal date 2026-11-06
Prestige Consumer Healthcare Inc. (PBH) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · NYSE
Rating · 90D
Unlock rating and forecasts
90-day forecast
Sign up free to reveal
30-day forecast
Alpha
Rank in coverage
of 5150 stocks scored
Rank correlation · 90D
20.0%
Spearman, 357 dates
Market Cap
$2.04B
mid-cap · #60 of 60 peers
Summary
Prestige Consumer Healthcare Inc. (PBH) stock forecast summary
Our AI scores Prestige Consumer Healthcare Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Prestige Consumer Healthcare Inc. is a mid-cap company with a market capitalization of $2.04B. It ranks number 60 by market capitalization among the 60 Pharmaceutical Preparations issuers in our coverage with a current forecast. Its P/B Ratio of 1.05x is the lowest of the 43 peers that report one.
For PBH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 20.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 10.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +3.1%, buy ≥ +1.5%, sell < -0.5%, strong sell < -1.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-11-06 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PBH included.
Price
PBH price chart and AI forecast
Cross-section · 2026-11-06
How PBH ranks among 5150 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Fundamentals · 2026-09-30
Prestige Consumer Healthcare Inc. (PBH) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Pharmaceutical Preparations peers listed below that report each metric.
Valuation & Market
| Metric | PBH | Rank |
|---|---|---|
| Market Cap | $2.04B | 60/60 |
| P/E Ratio | 12.01x | 26/33 |
| P/B Ratio | 1.05x | 43/43 |
| EPS | $3.58 | – |
| Book Value/Share | $41.05 | – |
| Revenue/Share | $24.64 | – |
| FCF/Share | $4.52 | – |
Profitability & Margins
| Metric | PBH | Rank |
|---|---|---|
| ROE | 8.3% | 19/39 |
| ROA | 3.4% | 20/43 |
| ROIC | 6.4% | 18/45 |
| Gross Margin | 52.5% | 33/36 |
| Operating Margin | 25.0% | 10/39 |
| Net Margin | 13.9% | 16/36 |
| EBT Margin | 16.0% | 19/46 |
| Tax Rate | 30.8% | – |
Financial Health
| Metric | PBH | Rank |
|---|---|---|
| Current Ratio | 2.92x | 26/58 |
| Quick Ratio | 1.86x | 21/43 |
| D/E Ratio | 1.43x | 16/48 |
| Financial Leverage | 2.43x | 15/48 |
| Working Capital | $324M | 46/58 |
Cash Flow
| Metric | PBH | Rank |
|---|---|---|
| Operating Cash Flow | $230M | 29/59 |
| Free Cash Flow | $214M | 25/50 |
| Capital Spending | -$16M | 21/50 |
| OCF Growth YoY | -12.8% | 26/35 |
| FCF Growth YoY | -19.8% | 26/33 |
| FCF/Sales | 18.4% | 22/42 |
| CapEx/Sales | 1.3% | 28/42 |
Operational Efficiency
| Metric | PBH | Rank |
|---|---|---|
| Asset Turnover | 0.25x | 33/39 |
| Receivables Turnover | 4.8x | 23/37 |
| Inventory Turnover | 3.1x | 10/35 |
| Fixed Assets Turnover | 10.0x | 19/41 |
| Days Sales Outstanding | 76 days | 15/37 |
| Days Inventory | 118 days | 26/35 |
| Payables Period | 29 days | 24/25 |
| Cash Conversion Cycle | 165 days | 13/23 |
Income Statement
| Metric | PBH | Rank |
|---|---|---|
| Total Revenue | $1.17B | 30/46 |
| Operating Income | $291M | 21/51 |
| Net Income | $162M | 22/47 |
| Cost of Goods Sold | $555M | 23/37 |
Dividend & Shareholder Information
| Metric | PBH | Rank |
|---|---|---|
| Shares Outstanding | 47M | – |
| Net Income Growth | -13.0% | 17/24 |
| EPS Growth | -11.8% | 17/25 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $492M | 10.4% of assets |
| Cash & Short-term Investments | $47M | 1.0% of assets |
| Accounts Receivable | $244M | 5.2% of assets |
| Inventory | $179M | 3.8% of assets |
| Total Liabilities | $2.78B | 58.8% of assets |
| Short-term Debt | $124M | 2.6% of assets |
Quarterly Financial Reports
PBH quarterly financials and insider trading
Industry Peers · Pharmaceutical Preparations
Prestige Consumer Healthcare Inc. (PBH) industry peers
Companies classified under the same SEC industry code as Prestige Consumer Healthcare Inc. (Pharmaceutical Preparations): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| PBH Prestige Consumer Healthcare Inc. | $2.04B | |
| LLY Eli Lilly & Co | $1.28T | |
| JNJ Johnson & Johnson | $664.95B | |
| ABBV Abbvie Inc. | $514.78B | |
| MRK Merck & Co., Inc. | $362.01B | |
| NVS Novartis Ag | $310.17B | |
| AZN Astrazeneca Plc | $288.97B | |
| ABT Abbott Laboratories | $191.15B | |
| NVO Novo Nordisk A S | $179.14B | |
| PFE Pfizer Inc | $167.51B | |
| VRTX Vertex Pharmaceuticals Inc / Ma | $137.50B | |
| BMY Bristol Myers Squibb Co | $127.02B | |
| SNY Sanofi | $115.97B | |
| GSK Gsk Plc | $101.70B | |
| REGN Regeneron Pharmaceuticals, Inc. | $93.11B | |
| TAK Takeda Pharmaceutical Co Ltd | $66.19B | |
| TEVA Teva Pharmaceutical Industries Ltd | $49.65B | |
| ONC Beone Medicines Ltd. | $46.26B | |
| GMAB Genmab A/S | $34.50B | |
| ZTS Zoetis Inc. | $33.93B | |
| RPRX Royalty Pharma Plc | $28.82B | |
| ROIV Roivant Sciences Ltd. | $26.45B | |
| INSM Insmed Inc | $25.10B | |
| UTHR United Therapeutics Corp | $24.11B | |
| VTRS Viatris Inc | $22.87B | |
| ALNY Alnylam Pharmaceuticals, Inc. | $20.89B | |
| ASND Ascendis Pharma A/S | $16.86B | |
| JAZZ Jazz Pharmaceuticals Plc | $15.24B | |
| BBIO Bridgebio Pharma, Inc. | $14.47B | |
| SMMT Summit Therapeutics Inc. | $13.03B | |
| ELAN Elanco Animal Health Inc | $12.86B | |
| RDY Dr Reddys Laboratories Ltd | $12.44B | |
| BMRN Biomarin Pharmaceutical Inc | $10.85B | |
| MDGL Madrigal Pharmaceuticals, Inc. | $9.24B | |
| TGTX Tg Therapeutics, Inc. | $9.20B | |
| SYRE Spyre Therapeutics, Inc. | $9.16B | |
| PTGX Protagonist Therapeutics, Inc | $8.54B | |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.22B | |
| CORT Corcept Therapeutics Inc | $7.87B | |
| PRAX Praxis Precision Medicines, Inc. | $7.75B | |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.73B | |
| ALKS Alkermes Plc. | $7.70B | |
| ABVX Abivax S.A. | $7.50B | |
| CYTK Cytokinetics Inc | $7.46B | |
| KNSA Kiniksa Pharmaceuticals International, Plc | $6.94B | |
| AXSM Axsome Therapeutics, Inc. | $6.93B | |
| ORKA Oruka Therapeutics, Inc. | $6.81B | |
| IONS Ionis Pharmaceuticals Inc | $6.55B | |
| AMRX Amneal Pharmaceuticals, Inc. | $6.43B | |
| MIRM Mirum Pharmaceuticals, Inc. | $6.07B | |
| BLTE Belite Bio, Inc | $6.07B | |
| LGND Ligand Pharmaceuticals Inc | $5.98B | |
| MANE Veradermics, Inc | $5.80B | |
| SUPN Supernus Pharmaceuticals, Inc. | $5.56B | |
| COGT Cogent Biosciences, Inc. | $5.49B | |
| PTCT Ptc Therapeutics, Inc. | $5.47B | |
| EWTX Edgewise Therapeutics, Inc. | $4.89B | |
| DNTH Dianthus Therapeutics, Inc. /De/ | $4.64B | |
| ERAS Erasca, Inc. | $4.64B | |
| TVTX Travere Therapeutics, Inc. | $4.44B |
Where PBH sits on the market map
Life Sciences · Pharmaceutical Preparations
News
Prestige Consumer Healthcare Inc. (PBH) stock news
Prestige Consumer Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2026
Prestige Consumer Healthcare Inc. reported earnings results for the second quarter and six months ended September 30, 2026. For the second quarter, the company reported sales was USD 332.9 million ...
Prestige Consumer Healthcare Inc. (PBH) Q4 2026 Earnings Call Transcript
Good day, and thank you for standing by. Welcome to Prestige Consumer Healthcare, Inc. Fourth Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference ...
FAQ
Prestige Consumer Healthcare Inc. (PBH) stock forecast FAQ
What is the Prestige Consumer Healthcare Inc. (PBH) stock forecast?
Our AI scores Prestige Consumer Healthcare Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Prestige Consumer Healthcare Inc. stock predictions?
For PBH, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 20.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 10.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Prestige Consumer Healthcare Inc. forecasts updated?
Prestige Consumer Healthcare Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Prestige Consumer Healthcare Inc.'s industry peers?
60 issuers in our coverage, PBH included, share the SEC industry code Pharmaceutical Preparations. The largest are: Eli Lilly & Co (LLY), Johnson & Johnson (JNJ), Abbvie Inc. (ABBV), Merck & Co., Inc. (MRK), Novartis Ag (NVS), Astrazeneca Plc (AZN).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.